Huminsulin Basal (Nph) Kwikpen (Insulin Human)

Huminsulin Basal (Nph) Kwikpen is indicated for the long‑term management of blood glucose in patients with diabetes.

• Type 1 diabetes mellitus as part of a basal insulin regimen.
• Type 2 diabetes mellitus when basal insulin is required.
• Adjunct to rapid‑acting insulin analogues for mixed‑dose therapy.
• Use in patients who need a once‑ or twice‑daily basal insulin schedule.
• Pediatric patients with type 1 diabetes when appropriate dosing is determined.
• Adults requiring stable basal insulin coverage during pregnancy if clinically indicated.

• Huminsulin Basal (Nph) Kwikpen delivers human insulin complexed with protamine, forming micro‑crystals that dissolve slowly after subcutaneous injection. The insulin molecules bind to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s tyrosine kinase pathway. This promotes translocation of GLUT‑4 transporters, increasing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering plasma glucose concentrations over an extended period. The effect typically lasts for up to 12–16 hours after injection.

Like other NPH insulin preparations, Huminsulin Basal (Nph) Kwikpen may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common

• Hypoglycemia (low blood glucose) that may cause shakiness, sweating, or dizziness.
• Redness, swelling, itching or bruising at the injection site.
• Lipodystrophy, presenting as localized thickening or loss of subcutaneous fat.
• Mild weight gain associated with improved glycemic control.

Serious

• Severe hypoglycemia with loss of consciousness, seizures, or need for assistance.
• Allergic reactions ranging from urticaria to anaphylaxis and angioedema.
• Insulin‑induced edema or significant fluid retention leading to swelling.
• Hypokalemia (low potassium) especially when combined with diuretics.

When prescribing or using Huminsulin Basal (Nph) Kwikpen, healthcare professionals and patients should observe several precautionary measures to reduce the risk of complications.

• Verify blood glucose before each dose to avoid hypoglycemia.
• Adjust the dose when there are changes in diet, exercise, or illness.
• Use caution in patients with renal or hepatic impairment.
• Monitor for signs of hypoglycemia during pregnancy and lactation if used.
• Educate patients on proper injection technique and rotation of sites.
• Review concomitant medications that may potentiate insulin effects.

Huminsulin Basal (Nph) Kwikpen can interact with other agents that affect glucose metabolism or insulin action.

Avoid

• Other insulins or insulin‑secretagogues (e.g., sulfonylureas) that may cause additive hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms.
• MAO‑inhibitors that can potentiate insulin’s glucose‑lowering effect.

Use with caution

• Oral antihyperglycemics (e.g., metformin, thiazolidinediones) requiring dose adjustments.
• Corticosteroids, which may increase insulin requirements.
• Diuretics, especially thiazides, that can alter potassium levels and affect insulin sensitivity.